Always interesting to know what "else" is going on. I will say it sounds limited to digestive tract (colon/gastric). It will be particularly interesting to see how fast something comes from the statement:

OncoMethylome said in August it was in advanced talks with several large companies over licensing rights to its colorectal test

I've always wondered why the NCI or a Canadian equivalent hasn't been mentioned (that I have noticed) regarding testing or advancement of Recaf. They can offer research and potentially expedite the development process for promising drugs/processes.